Copyright © 2015 by the American Osteopathic Association.

Slides:



Advertisements
Similar presentations
Faculty Disclosure Mikayla Spangler, PharmD, BCPS Dr. Spangler has listed no financial interest/arrangement that would be considered a conflict of interest.
Advertisements

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 7.
A The BYETTA mark and the BYETTA design mark are trademarks of Amylin Pharmaceuticals, Inc. All other trademarks are property of their respective.
The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose- Ranging.
GLP-1 agonists Ian Gallen Consultant Community Diabetologist
Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Insulin Therapy for Type 2 Diabetes Mellitus JAMA.
Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Projection of Diabetic Retinopathy and Other Major.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
James Thrasher, MD  The American Journal of Medicine 
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2005 American Medical Association. All rights reserved.
Copyright © 2015 by the American Osteopathic Association.
From: Pharmacologic Therapy for Type 2 Diabetes Mellitus
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Matthew P. Gilbert, DO, MPH, Richard E. Pratley, MD 
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Algorithm for the metabolic management of type 2 diabetes mellitus; reinforce lifestyle interventions at every visit and check hemoglobin A1c every 3 months.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Figure 4 Effect of dapagliflozin on HbA1c and body weight
Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.
Volume 70, Issue 8, Pages (October 2006)
Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis  Patricia M.
James Thrasher, MD  The American Journal of Medicine 
George Dailey, MD  Mayo Clinic Proceedings 
Matthew P. Gilbert, DO, MPH, Richard E. Pratley, MD 
Change in HbA1c and weight compared with baseline variables for the liraglutide group and the placebo group. Change in HbA1c and weight compared with baseline.
(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.
Glucose-lowering medication in type 2 diabetes: overall approach.
The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.
Glycemic control and body weight over 52 weeks.
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 7.
Patient disposition and study protocol.
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 5.
Presentation transcript:

Copyright © 2015 by the American Osteopathic Association. From: Application of Incretin Mimetics and Dipeptidyl Peptidase IV Inhibitors in Managing Type 2 Diabetes Mellitus J Am Osteopath Assoc. 2007;107(suppl_3):S10-S16. Figure Legend: Effects of exenatide on glycemic control of patients with type 2 diabetes mellitus who were also using currently available oral medications (metformin and/or sulfonylurea). *P <.001 versus placebo; †P <.001 versus placebo. Abbreviations: BID, twice a day; HbA1c, hemoglobin A1c. (Reprinted with permission of the National Diabetes Education Initiative [NDEI]. Sources: DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-1100; Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; for the Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635; Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-1091.) Date of download: 10/8/2017 Copyright © 2015 by the American Osteopathic Association. All rights reserved.

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.